ALNY
ALNYLAM PHARMACEUTICALS, INC.
$282.85
-2.26%
$37.8B
No data for this timeframe.
Vol
Market Cap$37.8B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (76%)
Inst. Holders50 funds
Inst. Value$29.9B
Inst. Activity30 buys / 20 sells
Insider Activity0B / 15S
Insider Net $-$3.0M
SEC Reports3
Recent Activity
Jun 12, 2026
short_volume
Short Volume: ALNY — 55.6% short (0.4M / 0.7M)
Short: 390,444 | Exempt: 938 | TRF Vol: 701,645 | Short Ratio: 55.6% | Off-exchange volume (dark poo
Jun 1, 2026
Insider
PYOTT DAVID E I sold 921 shares
Director @ $297.71 ($274.2K)
Jun 1, 2026
Insider
PYOTT DAVID E I acquired via exercise 3,830 shares
Director
Jun 1, 2026
Insider
Cravatt Benjamin was granted 4,393 shares
Director
Mar 6, 2026
SEC
Seven Alnylam Pharmaceuticals insiders executed trades over the past week, with three C-suite executives selling a combi
CLUSTER — Impact 3/10
Mar 5, 2026
SEC
A cluster of insider transactions at Alnylam Pharmaceuticals over the past week includes open-market sales by the CSO an
CLUSTER — Impact 3/10
Feb 28, 2026
SEC
Three major institutions, including sovereign wealth fund Norges Bank, accumulated $1.06B in new positions in Alnylam Ph
INST-CLUSTER — Impact 7/10
Inst.
Capital World Investors — TRIM
10,802,348 shares ($3.6B)
Price Targets
$438.52
+55.0% upside
Strong Buy
Current $282.85
Low $310.00
Median $429.00
High $550.00
25 analysts
$310.00
$550.00
Analyst Ratings
7Strong Buy
21Buy
9Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 4, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 19, 2026 | Citigroup | INITIATE | Buy |
| May 5, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 1, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| May 1, 2026 | Wells Fargo | MAINTAIN | Equal-Weight → Equal-Weight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $2.17 ▲ +4.8% | $1.65 — $3.49 | 577% YoY | 14 |
| Next Q | $2.46 ▲ +3.8% | $1.53 — $3.74 | -15% YoY | 14 |
| Current FY | $9.50 ▲ +1.9% | $7.94 — $13.00 | 87% YoY | 16 |
| Next FY | $13.77 | $11.10 — $18.21 | 45% YoY | 16 |
Latest Reports
NEUTRAL
CLUSTER
3/10
Seven Alnylam Pharmaceuticals insiders executed trades over the past week, with three C-suite executives selling a combi
Mar 6, 2026
NEUTRAL
CLUSTER
3/10
A cluster of insider transactions at Alnylam Pharmaceuticals over the past week includes open-market sales by the CSO an
Mar 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $4.8B | — |
| Capital World Investors | $3.6B | TRIM |
| BlackRock, Inc. | $3.5B | — |
| Capital Research Global Investors | $3.1B | ADD |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2.1B | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | PYOTT DAVID | SELL | $274.2K |
| Jun 1, 2026 | PYOTT DAVID | M | $0.00 |
| Jun 1, 2026 | Cravatt Benjamin | A | $0.00 |
| May 20, 2026 | Arbuckle Stuart | A | $0.00 |
| May 20, 2026 | Arbuckle Stuart | A | $0.00 |
50 institutional holders with $29.9B total value (90,536,242 shares) as of 2026-Q1. Top holders: FMR, Capital, BlackRock,. Net buying activity: 30 institutions added/increased vs 20 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 14,579,166 | $4.8B | 16.1% | — |
| 2 | Capital World Investors | 10,802,348 | $3.6B | 11.9% | TRIM -33.7% |
| 3 | BlackRock, Inc. | 10,444,908 | $3.5B | 11.5% | — |
| 4 | Capital Research Global Investors | 9,471,181 | $3.1B | 10.5% | ADD +39.7% |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 6,491,280 | $2.1B | 7.2% | — |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 5,946,706 | $2.0B | 6.6% | — |
| 7 | STATE STREET CORP | 3,322,698 | $1.1B | 3.7% | — |
| 8 | BAILLIE GIFFORD & CO | 2,493,866 | $825.1M | 2.8% | — |
| 9 | TWO SIGMA INVESTMENTS, LP | 1,992,577 | $659.3M | 2.2% | — |
| 10 | WELLINGTON MANAGEMENT GROUP LLP | 1,935,925 | $640.5M | 2.1% | — |
| 11 | DODGE & COX | 1,929,253 | $638.3M | 2.1% | — |
| 12 | Clearbridge Investments, LLC | 1,356,036 | $448.7M | 1.5% | DOUBLED +127.1% |
| 13 | Invesco Ltd. | 1,291,726 | $427.4M | 1.4% | TRIM -40.4% |
| 14 | MARSHALL WACE, LLP | 1,099,318 | $363.7M | 1.2% | ADD +99.9% |
| 15 | D. E. Shaw & Co., Inc. | 1,059,062 | $350.4M | 1.2% | — |
| 16 | MORGAN STANLEY | 1,002,681 | $331.8M | 1.1% | — |
| 17 | BANK OF AMERICA CORP /DE/ | 966,912 | $319.9M | 1.1% | ADD +41.1% |
| 18 | Legal & General Group Plc | 934,881 | $309.3M | 1.0% | — |
| 19 | VANGUARD FIDUCIARY TRUST CO | 840,888 | $278.2M | 0.9% | — |
| 20 | ROYAL BANK OF CANADA | 791,515 | $261.9M | 0.9% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Capital World Investors | TRIM | 16,301,772 | 10,802,348 | -33.7% | $3.6B | 2026-Q1 |
| Capital Research Global Investors | ADD | 6,779,708 | 9,471,181 | +39.7% | $3.1B | 2026-Q1 |
| Clearbridge Investments, LLC | DOUBLED | 597,013 | 1,356,036 | +127.1% | $448.7M | 2026-Q1 |
| Invesco Ltd. | TRIM | 2,165,840 | 1,291,726 | -40.4% | $427.4M | 2026-Q1 |
| MARSHALL WACE, LLP | ADD | 549,922 | 1,099,318 | +99.9% | $363.7M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 685,177 | 966,912 | +41.1% | $319.9M | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | DOUBLED | 63,412 | 662,365 | +944.5% | $219.2M | 2026-Q1 |
| FRANKLIN RESOURCES INC | TRIM | 787,623 | 470,390 | -40.3% | $155.6M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 301,865 | 384,205 | +27.3% | $127.1M | 2026-Q1 |
| FIRST TRUST ADVISORS LP | ADD | 256,954 | 382,701 | +48.9% | $126.6M | 2026-Q1 |
| Nuveen, LLC | TRIM | 565,789 | 322,232 | -43.0% | $106.6M | 2026-Q1 |
| PINEBRIDGE INVESTMENTS LLC | DOUBLED | 100,199 | 271,419 | +170.9% | $89.8M | 2026-Q1 |
| Woodline Partners LP | DOUBLED | 1,759 | 243,883 | +13764.9% | $80.7M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | ADD | 181,137 | 239,941 | +32.5% | $79.4M | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | ADD | 109,604 | 180,012 | +64.2% | $59.6M | 2026-Q1 |
| ENVESTNET ASSET MANAGEMENT INC | ADD | 120,521 | 171,797 | +42.5% | $56.8M | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | TRIM | 198,613 | 148,488 | -25.2% | $49.1M | 2026-Q1 |
| CAPITAL FUND MANAGEMENT S.A. | DOUBLED | 20,940 | 140,109 | +569.1% | $46.4M | 2026-Q1 |
| Assenagon Asset Management S.A. | DOUBLED | 25,590 | 128,896 | +403.7% | $42.6M | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | TRIM | 240,052 | 88,278 | -63.2% | $29.2M | 2026-Q1 |
| LMR Partners LLP | ADD | 59,022 | 74,661 | +26.5% | $24.7M | 2026-Q1 |
| NEOS Investment Management LLC | ADD | 40,701 | 68,873 | +69.2% | $22.8M | 2026-Q1 |
| Trexquant Investment LP | DOUBLED | 26,741 | 61,760 | +131.0% | $20.4M | 2026-Q1 |
| PFA Pension, Forsikringsaktieselskab | ADD | 35,405 | 59,700 | +68.6% | $19.8M | 2026-Q1 |
| STIFEL FINANCIAL CORP | DOUBLED | 20,427 | 49,954 | +144.5% | $16.5M | 2026-Q1 |
16 unique insiders with 50 transactions. Net insider value: -$3.0M ($0.00 bought, $3.0M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | PYOTT DAVID E I | Director | SELL | 921 | $297.71 | $274.2K |
| Jun 1, 2026 | PYOTT DAVID E I | Director | EXERCISE | 3,830 | — | — |
| Jun 1, 2026 | Cravatt Benjamin | Director | AWARD | 4,393 | — | — |
| May 20, 2026 | Arbuckle Stuart A | Director | AWARD | 671 | — | — |
| May 20, 2026 | Arbuckle Stuart A | Director | AWARD | 1,441 | — | — |
| May 20, 2026 | BRANDICOURT OLIVIER | Director | AWARD | 1,441 | — | — |
| May 20, 2026 | Ausiello Dennis A | Director | AWARD | 1,441 | — | — |
| May 20, 2026 | Ausiello Dennis A | Director | AWARD | 671 | — | — |
| May 20, 2026 | BRANDICOURT OLIVIER | Director | AWARD | 671 | — | — |
| May 20, 2026 | HAMBURG MARGARET A | Director | AWARD | 671 | — | — |
| May 20, 2026 | HAMBURG MARGARET A | Director | AWARD | 1,441 | — | — |
| May 20, 2026 | KELLOGG PETER N | Director | AWARD | 671 | — | — |
| May 20, 2026 | KELLOGG PETER N | Director | AWARD | 1,441 | — | — |
| May 20, 2026 | PYOTT DAVID E I | Director | AWARD | 1,441 | — | — |
| May 20, 2026 | PYOTT DAVID E I | Director | AWARD | 671 | — | — |
| May 20, 2026 | Sigal Charles Elliott | Director | AWARD | 1,441 | — | — |
| May 20, 2026 | Reitan Colleen F | Director | AWARD | 1,441 | — | — |
| May 20, 2026 | Reitan Colleen F | Director | AWARD | 671 | — | — |
| May 20, 2026 | SCHULMAN AMY W | Director | AWARD | 838 | — | — |
| May 20, 2026 | SCHULMAN AMY W | Director | AWARD | 1,802 | — | — |
| May 20, 2026 | Sigal Charles Elliott | Director | AWARD | 671 | — | — |
| May 13, 2026 | SCHULMAN AMY W | Director | EXERCISE | 11,250 | $70.20 | $789.8K |
| Apr 6, 2026 | McLaughlin Melissa | Chief Human Resources Officer | SELL | 56 | $320.14 | $17.9K |
| Apr 2, 2026 | McLaughlin Melissa | Chief Human Resources Officer | SELL | 265 | $316.61 | $83.9K |
| Mar 5, 2026 | Garg Pushkal | EVP Chief R&D | SELL | 654 | $322.33 | $210.8K |
| Mar 5, 2026 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | SELL | 124 | $321.81 | $39.9K |
| Mar 4, 2026 | Greenstreet Yvonne | Chief Executive Officer | SELL | 135 | $319.03 | $43.1K |
| Mar 4, 2026 | Tanguler Tolga | EVP, Chief Commercial Officer | SELL | 106 | $319.03 | $33.8K |
| Mar 4, 2026 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | SELL | 29 | $319.03 | $9.3K |
| Mar 4, 2026 | Poulton Jeffrey V. | EVP, Chief Financial Officer | SELL | 114 | $319.03 | $36.4K |
| Mar 4, 2026 | Garg Pushkal | EVP Chief R&D | SELL | 106 | $319.03 | $33.8K |
| Mar 3, 2026 | Garg Pushkal | EVP Chief R&D | SELL | 355 | $316.74 | $112.4K |
| Mar 3, 2026 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | SELL | 289 | $316.55 | $91.5K |
| Mar 2, 2026 | Poulton Jeffrey V. | EVP, Chief Financial Officer | AWARD | 4,769 | — | — |
| Mar 2, 2026 | Greenstreet Yvonne | Chief Executive Officer | AWARD | 30,425 | — | — |
| Mar 2, 2026 | Greenstreet Yvonne | Chief Executive Officer | AWARD | 110,746 | — | — |
| Mar 2, 2026 | Greenstreet Yvonne | Chief Executive Officer | AWARD | 13,844 | — | — |
| Mar 2, 2026 | Poulton Jeffrey V. | EVP, Chief Financial Officer | AWARD | 10,480 | — | — |
| Mar 2, 2026 | Garg Pushkal | EVP Chief R&D | AWARD | 4,769 | — | — |
| Mar 2, 2026 | Garg Pushkal | EVP Chief R&D | AWARD | 10,480 | — | — |
| Mar 2, 2026 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | AWARD | 3,688 | — | — |
| Mar 2, 2026 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | AWARD | 8,105 | — | — |
| Feb 27, 2026 | Poulton Jeffrey V. | EVP, Chief Financial Officer | EXERCISE | 1,908 | — | — |
| Feb 27, 2026 | Tanguler Tolga | EVP, Chief Commercial Officer | EXERCISE | 1,666 | — | — |
| Feb 27, 2026 | Greenstreet Yvonne | Chief Executive Officer | EXERCISE | 5,921 | — | — |
| Feb 27, 2026 | Garg Pushkal | EVP Chief R&D | EXERCISE | 1,908 | — | — |
| Feb 23, 2026 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | AWARD | 158 | — | — |
| Feb 17, 2026 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | SELL | 2,041 | $331.96 | $677.5K |
| Feb 13, 2026 | Poulton Jeffrey V. | EVP, Chief Financial Officer | SELL | 2,242 | $310.08 | $695.2K |
| Feb 13, 2026 | Tanguler Tolga | EVP, Chief Commercial Officer | SELL | 1,959 | $310.08 | $607.4K |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 4.3/10.
NEUTRAL
CLUSTER
3/10
Seven Alnylam Pharmaceuticals insiders executed trades over the past week, with three C-suite execut
Mar 6, 2026
NEUTRAL
CLUSTER
3/10
A cluster of insider transactions at Alnylam Pharmaceuticals over the past week includes open-market
Mar 5, 2026
BULLISH
INST-CLUSTER
7/10
Three major institutions, including sovereign wealth fund Norges Bank, accumulated $1.06B in new pos
Feb 28, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (76% buy). Based on 37 analysts: 7 strong buy, 21 buy, 9 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$438.52 mean target
+55.0% upside
Strong Buy (1.79)
$310.00 Low
$550.00 High
| Metric | Value |
|---|---|
| Current Price | $282.85 |
| Target Low | $310.00 |
| Target Mean | $438.52 |
| Target Median | $429.00 |
| Target High | $550.00 |
| # Analysts | 25 |
| Recommendation | Strong Buy (1.79) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$2.17 | $1.65 | $3.49 | 576.7% | +4.8% | 3↑ 8↓ | $1.3B | 70.8% | 14 |
| Next Q 2026-09-30 |
$2.46 | $1.53 | $3.74 | -15.1% | +3.8% | 1↑ 10↓ | $1.5B | 18.5% | 14 |
| Current FY 2026-12-31 |
$9.50 | $7.94 | $13.00 | 87.1% | +1.9% | 7↑ 6↓ | $5.6B | 51.5% | 16 |
| Next FY 2027-12-31 |
$13.77 | $11.10 | $18.21 | 44.8% | -0.2% | 4↑ 9↓ | $7.3B | 30.2% | 16 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $2.165 | |
| 7d ago | $2.165 | |
| 30d ago | $2.066 | +0.100 |
| 60d ago | $2.136 | +0.029 |
| 90d ago | $2.181 | -0.016 |
14 analyst firms have rated this stock: 1 upgrades, 1 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 4, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 19, 2026 | Citigroup | INITIATE | — | Buy |
| May 5, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 1, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| May 1, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Apr 13, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Mar 25, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 25, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 16, 2026 | Jefferies | DOWNGRADE | Buy | Hold |
| Feb 18, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 17, 2026 | Freedom Broker | UPGRADE | Hold | Buy |
| Feb 17, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Feb 13, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Feb 12, 2026 | Needham | MAINTAIN | Buy | Buy |
| Jan 30, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Jan 30, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Jan 30, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 28, 2026 | Barclays | INITIATE | — | Overweight |
| Jan 20, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Jan 20, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Jan 12, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Jan 12, 2026 | Needham | MAINTAIN | Buy | Buy |
| Jan 8, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Dec 15, 2025 | Leerink Partners | MAINTAIN | Market Perform | Market Perform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 21 | 9 | 0 | 0 | 76% | |
| May 1, 2026 | 7 | 20 | 9 | 0 | 0 | 75% | |
| Apr 1, 2026 | 7 | 20 | 9 | 0 | 0 | 75% | |
| Mar 1, 2026 | 8 | 20 | 8 | 0 | 0 | 78% | |
| Feb 1, 2026 | 8 | 19 | 9 | 0 | 0 | 75% | |
| Jan 1, 2026 | 8 | 19 | 9 | 0 | 0 | 75% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 12, 2026
short_volume
Short Volume: ALNY — 55.6% short (0.4M / 0.7M)
Short: 390,444 | Exempt: 938 | TRF Vol: 701,645 | Short Ratio: 55.6% | Off-exchange volume (dark pool + OTC)
May 18, 2026
dark_pool
Dark Pool: ALNY — 1.0M shares, 49,330 trades
Week starting 2026-05-18. Total ATS volume: 970,996 shares across 49,330 trades.
May 12, 2026
short_interest
FTD: ALNY — 18,560 shares ($5.3M) failed to deliver
Settlement: 20260512, Price: $284.84, FTD Value: $5,286,630.4, ALYNLAM PHARMACEUTICALS INC
May 11, 2026
dark_pool
Dark Pool: ALNY — 1.5M shares, 54,875 trades
Week starting 2026-05-11. Total ATS volume: 1,488,504 shares across 54,875 trades.
May 4, 2026
dark_pool
Dark Pool: ALNY — 1.8M shares, 59,669 trades
Week starting 2026-05-04. Total ATS volume: 1,833,195 shares across 59,669 trades.
Apr 30, 2026
Clinical Trial
A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension
Phase Phase 2 — COMPLETED
Apr 30, 2026
earnings_calendar
ALNY Q1 2026 Earnings Scheduled — 2026-04-30
Apr 30, 2026
short_volume
Short Volume: ALNY — 65.3% short (0.7M / 1.1M)
Short: 695,814 | Exempt: 3 | TRF Vol: 1,064,804 | Short Ratio: 65.3% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
dark_pool
Dark Pool: ALNY — 2.6M shares, 64,237 trades
Week starting 2026-04-27. Total ATS volume: 2,618,547 shares across 64,237 trades.
Apr 21, 2026
short_volume
Short Volume: ALNY — 67.5% short (0.4M / 0.7M)
Short: 440,849 | Exempt: 199 | TRF Vol: 652,848 | Short Ratio: 67.5% | Off-exchange volume (dark pool + OTC)
Apr 20, 2026
Clinical Trial
APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
Phase Phase 3 — COMPLETED
Apr 20, 2026
dark_pool
Dark Pool: ALNY — 1.4M shares, 47,858 trades
Week starting 2026-04-20. Total ATS volume: 1,433,432 shares across 47,858 trades.
Apr 13, 2026
dark_pool
Dark Pool: ALNY — 1.7M shares, 51,701 trades
Week starting 2026-04-13. Total ATS volume: 1,653,699 shares across 51,701 trades.
Apr 7, 2026
short_volume
Short Volume: ALNY — 77.6% short (0.5M / 0.7M)
Short: 540,526 | Exempt: 47 | TRF Vol: 696,367 | Short Ratio: 77.6% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
dark_pool
Dark Pool: ALNY — 1.9M shares, 60,451 trades
Week starting 2026-04-06. Total ATS volume: 1,930,840 shares across 60,451 trades.
Apr 6, 2026
short_volume
Short Volume: ALNY — 63.9% short (0.3M / 0.5M)
Short: 329,515 | Exempt: 4,056 | TRF Vol: 515,803 | Short Ratio: 63.9% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
dark_pool
Dark Pool: ALNY — 1.3M shares, 40,483 trades
Week starting 2026-03-30. Total ATS volume: 1,324,948 shares across 40,483 trades.
Mar 2, 2026
Clinical Trial
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
Phase Phase 2 — COMPLETED